Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: A review of the literature

2011 ◽  
Vol 47 (10) ◽  
pp. 1468-1475 ◽  
Author(s):  
Christophe Le Tourneau ◽  
Albiruni R.A. Razak ◽  
Hui K. Gan ◽  
Simona Pop ◽  
Véronique Diéras ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Phase I ◽  
Cancer Clinical Trials ◽  
Targeted Agents ◽  
Review Of The Literature ◽  
Molecularly Targeted Agents ◽  
Definition Of ◽  
Dose Limiting Toxicity

Outcomes of Patients with Metastatic Melanoma Treated with Molecularly Targeted Agents in Phase I Clinical Trials

Oncology ◽  
2011 ◽  
Vol 81 (2) ◽  
pp. 135-140 ◽  
Author(s):  
Montserrat Blanco Codesido ◽  
Andre Tesainer Brunetto ◽  
Sophia Frentzas ◽  
Victor Moreno Garcia ◽  
Dionysis Papadatos-Pastos ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Phase I ◽  
Metastatic Melanoma ◽  
Targeted Agents ◽  
Phase I Clinical Trials ◽  
Molecularly Targeted Agents

scholarly journals Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents

PLoS ONE ◽  
2012 ◽  
Vol 7 (12) ◽  
pp. e51039 ◽  
Author(s):  
Christophe Le Tourneau ◽  
Hui K. Gan ◽  
Albiruni R. A. Razak ◽  
Xavier Paoletti
Keyword(s):  
Phase I ◽  
Dose Escalation ◽  
Dose Finding ◽  
Phase I Trials ◽  
Targeted Agents ◽  
Molecularly Targeted Agents

384 POSTER Effect of selection of QTc formula on eligibility of patients for phase I cancer clinical trials

2008 ◽  
Vol 6 (12) ◽  
pp. 120
Author(s):  
M. Benjamin ◽  
D. Casa ◽  
W. Tembe ◽  
B. Piper ◽  
S. Anthony ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Phase I ◽  
Cancer Clinical Trials ◽  
Selection Of
Sign in / Sign up

Export Citation Format

Share Document